These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28858439)

  • 21. Gender Differences and Other Factors Associated with Weight Gain Following Initiation of Infliximab: A Post Hoc Analysis of Clinical Trials.
    Christian KE; Russman KM; Rajan DP; Barr EA; Cross RK
    Inflamm Bowel Dis; 2020 Jan; 26(1):125-131. PubMed ID: 31265730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term risk of infection in patients with Crohn's disease on anti-TNF treatment: A prospective single-center cohort study in China.
    Li Y; Shu HJ; Lu H; Yang H; Li J; Tan B; Qian JM
    J Dig Dis; 2017 Jul; 18(7):388-394. PubMed ID: 28644565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).
    Fernández-Salazar L; Muñoz F; Barrio J; Muñoz C; Pajares R; Rivero M; Prieto V; Legido J; Bouhmidi A; Herranz M; Fernández N; Sánchez-Ocaña R; Joao D; Santos F
    Scand J Gastroenterol; 2016; 51(2):186-95. PubMed ID: 26200929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.
    Roblin X; Marotte H; Leclerc M; Del Tedesco E; Phelip JM; Peyrin-Biroulet L; Paul S
    J Crohns Colitis; 2015 Jul; 9(7):525-31. PubMed ID: 25895875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is mean platelet volume a good predictor of sustained response to one year infliximab therapy in pediatric patients with Crohn's disease?
    Herman R; Sładek M; Pieczarkowski S; Dumnicka P; Fyderek K
    Folia Med Cracov; 2017; 57(2):63-71. PubMed ID: 29121038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab.
    Thiebault H; Boyard-Lasselin P; Guignant C; Guillaume N; Wacrenier A; Sabbagh C; Rebibo L; Brazier F; Meynier J; Nguyen-Khac E; Dupas JL; Goëb V; Fumery M
    Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):876-81. PubMed ID: 27101404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment adherence and use of complementary and alternative medicine in patients with inflammatory bowel disease].
    Lakatos L; Czeglédi Z; Dávid G; Kispál Z; Kiss LS; Palatka K; Kristóf T; Molnár T; Salamon A; Demeter P; Miheller P; Szamosi T; Banai J; Papp M; Bene L; Kovács A; Rácz I; Lakatos PL
    Orv Hetil; 2010 Feb; 151(7):250-8. PubMed ID: 20133244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment with infliximab for pediatric Crohn's disease: Nationwide survey of Japan.
    Hosoi K; Ohtsuka Y; Fujii T; Kudo T; Matsunaga N; Tomomasa T; Tajiri H; Kunisaki R; Ishige T; Yamada H; Arai K; Yoden A; Ushijima K; Aomatsu T; Nagata S; Uchida K; Takeuchi K; Shimizu T
    J Gastroenterol Hepatol; 2017 Jan; 32(1):114-119. PubMed ID: 27478130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
    Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
    Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of concomitant elemental diet therapy in scheduled infliximab therapy in patients with Crohn's disease to prevent loss of response.
    Kamata N; Oshitani N; Watanabe K; Watanabe K; Hosomi S; Noguchi A; Yukawa T; Yamagami H; Shiba M; Tanigawa T; Watanabe T; Tominaga K; Fujiwara Y; Arakawa T
    Dig Dis Sci; 2015 May; 60(5):1382-8. PubMed ID: 25532505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
    Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
    J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea.
    Seo H; Chang K; Lee SH; Song EM; Kim GU; Seo M; Lee HS; Hwang SW; Yang DH; Kim KJ; Ye BD; Byeon JS; Myung SJ; Yang SK; Park SH
    Scand J Gastroenterol; 2017 Aug; 52(8):857-863. PubMed ID: 28502189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis.
    Kobayashi T; Suzuki Y; Motoya S; Hirai F; Ogata H; Ito H; Sato N; Ozaki K; Watanabe M; Hibi T
    J Gastroenterol; 2016 Mar; 51(3):241-51. PubMed ID: 26162647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Costs of providing infusion therapy for patients with inflammatory bowel disease in a hospital-based infusion center setting.
    Afzali A; Ogden K; Friedman ML; Chao J; Wang A
    J Med Econ; 2017 Apr; 20(4):409-422. PubMed ID: 28112566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease.
    Billiet T; Papamichael K; de Bruyn M; Verstockt B; Cleynen I; Princen F; Singh S; Ferrante M; Van Assche G; Vermeire S
    J Crohns Colitis; 2015 Dec; 9(12):1120-6. PubMed ID: 26351386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn's disease.
    Sumi R; Nakajima K; Iijima H; Wasa M; Shinzaki S; Nezu R; Inoue Y; Ito T
    Surg Today; 2016 Aug; 46(8):922-9. PubMed ID: 26438200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.
    Cortes X; Borrás-Blasco J; Molés JR; Boscá M; Cortés E
    PLoS One; 2015; 10(5):e0128156. PubMed ID: 26011514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of infliximab in treating patients with ulcerative colitis: experiences from a single medical center in southern China.
    Zhou YL; Xie S; Wang P; Zhang T; Lin MY; Tan JS; Zhi FC; Jiang B; Chen Y
    J Dig Dis; 2014 Sep; 15(9):483-90. PubMed ID: 24828856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medication non-adherence in adult patients affected by inflammatory bowel disease: a critical review and update of the determining factors, consequences and possible interventions.
    Lenti MV; Selinger CP
    Expert Rev Gastroenterol Hepatol; 2017 Mar; 11(3):215-226. PubMed ID: 28099821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fecal Microbiota Alterations Associated With Clinical and Endoscopic Response to Infliximab Therapy in Crohn's Disease.
    Zhuang X; Tian Z; Feng R; Li M; Li T; Zhou G; Qiu Y; Chen B; He Y; Chen M; Zeng Z; Zhang S
    Inflamm Bowel Dis; 2020 Oct; 26(11):1636-1647. PubMed ID: 33026078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.